- Home
- ACAD vs BNL Comparison
ACAD vs BNL Comparison
Compare ACAD & BNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- BNL
- Stock Information
- Founded
- ACAD 1993
- BNL 2007
- Country
- ACAD United States
- BNL United States
- Employees
- ACAD N/A
- BNL N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- BNL Real Estate Investment Trusts
- Sector
- ACAD Health Care
- BNL Real Estate
- Exchange
- ACAD Nasdaq
- BNL Nasdaq
- Market Cap
- ACAD 4.0B
- BNL 3.0B
- IPO Year
- ACAD 2004
- BNL 2020
- Fundamental
- Price
- ACAD $25.99
- BNL $18.59
- Analyst Decision
- ACAD Buy
- BNL Hold
- Analyst Count
- ACAD 20
- BNL 6
- Target Price
- ACAD $28.63
- BNL $18.50
- AVG Volume (30 Days)
- ACAD 2.0M
- BNL 1.7M
- Earning Date
- ACAD 08-06-2025
- BNL 10-29-2025
- Dividend Yield
- ACAD N/A
- BNL 6.24%
- EPS Growth
- ACAD 615.00
- BNL N/A
- EPS
- ACAD 1.33
- BNL 0.52
- Revenue
- ACAD $1,018,885,000.00
- BNL $442,203,000.00
- Revenue This Year
- ACAD $14.01
- BNL $4.91
- Revenue Next Year
- ACAD $11.72
- BNL $5.88
- P/E Ratio
- ACAD $19.61
- BNL $35.83
- Revenue Growth
- ACAD 14.41
- BNL 3.85
- 52 Week Low
- ACAD $13.40
- BNL $13.96
- 52 Week High
- ACAD $26.65
- BNL $19.15
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- BNL 81.06
- Support Level
- ACAD $25.14
- BNL $18.22
- Resistance Level
- ACAD $26.65
- BNL $18.45
- Average True Range (ATR)
- ACAD 0.67
- BNL 0.27
- MACD
- ACAD 0.04
- BNL 0.14
- Stochastic Oscillator
- ACAD 70.27
- BNL 97.22
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About BNL Broadstone Net Lease Inc.
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.